[1] DAVIES M J,THOMAS A.Thrombosis and acute coronary-artery lesions in sudden cardiac ischemia death[J].N Engl J Med,1984,310:1137-1140.
[2] SILBER S,ALBERTSSON P,AVILÉS F F,et al.Task force for percutaneous coronary interventions of the European Society of Cardiology.Guidelines for percutaneous coronary interventions[J].Eur Heart J,2005,26:804-847.
[3] SVILAAS T,VLAAR P J,van der HORST I C,et al.Thrombus aspiration during primary percutaneous coronary intervention[J].N Engl J Med,2008,358:557-567.
[4] de LUCA G,SURYAPRANATA H,STONE G W,et al.Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction[J].JAMA,2005,293:1759-1765.
[5] ANTONIUCCI D,RODRIGUEZ A,HEMPEL A,et al.A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction[J].J Am Coll Cardiol,2003,42:1879-1885.
[6] KARVOUNI E,KATRITSIS D G,IOANNIDIS J P,et al.Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions[J].J Am Coll Cardiol,2003,41:26-32.
[7] BELLANDI F,MAIOLI M,GALLOPIN M,et al.Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention[J].Catheter Cardiovasc Interv,2004,62:186-192.
[8] BURZOTTA F,ROMAGNOLI E,TRANI C,et al.Intracoronary administration of abciximab acutely increases flow through culprit vessels of patients with acute coronary syndromes undergoing percutaneous coronary intervention[J].Circulation,2003,108:138.
[9] ROMAGNOLI E,BURZOTTA F,TRANI C,et al.Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI[J].Int J Cardiol,2005,105:250-255.
[10] 中华医学会心血管病学分会介入心脏病学组,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012(简本)[J].中华心血管病杂志,2012,40:271-277.
[11] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.抗血小板治疗中国专家共识[J].中华心血管病杂志,2013,41:183-194.
[12] STEG P G,JAMES S K,ATAR D,et al.Task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC).ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J].Eur Heart J,2012,33:2569-2619.
[13] van't HOF A W,TEN BERG J,HEESTERMANS T,et al.Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (ON-TIME 2):a multicentre,doubleblind,randomised controlled trial[J].Lancet,2008,372(9638):537-546.
[14] DUDEK D,SIUDAK Z,JANZON M,et al.European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab-EUROTRANSFER Registry[J].Am Heart J,2008,156:1147-1154.
[15] de LUCA G,GIBSON C M,BELLANDI F,et al.Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation:an individual patient data meta-analysis[J].Heart,2008,94:1548-1558.
[16] XU Q,YIN J,SI L Y,et al.Efficacy and safety of early versus late glycoprotein GPI for PCI[J].Int J Cardiol,2013,162:210-219.
[17] KUSHNER F G,HAND M,SMITH S C,et al.2009 focused updates:ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2009,54:2205-2241.
[18] FRIEDLAND S,EISENBERG M J,SHIMONY A.Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome[J].Am J Cardiol,2011,108:1244-1251.
[19] NAVARESE E P,KOZINSKI M,OBONSKA K,et al.Clinical efficacy and safety of intracoronary vs.intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention:a meta-analysis of randomized trials[J].Platelets,2012,23:274-281.
[20] THIELE H,WHRLE J,HAMBRECHT R,et al.Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction:a randomised trial[J].Lancet,2012,379:923-931.
[21] KUBICA J,KOZISKI M,NAVARESE E P,et al.Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction:a systematic review and meta-analysis of randomized clinical trials[J].Cardiol J,2012,19:230-242.
[22] HANSEN P R,IVERSEN A,ABDULLA J.Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention:a systematic review and meta-analysis[J].J Invasive Cardiol,2010,22:278-282.
[23] NAVARESE E P,KOZINSKI M,OBONSKA K,et al.Clinical efficacy and safety of intracoronary vs.intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention:a meta-analysis of randomized trials[J].Platelets,2012,23(4):274-281. |